dc.contributor | Vall d'Hebron Barcelona Hospital Campus |
dc.contributor.author | Tabernero Caturla, Josep |
dc.contributor.author | André, Fabrice |
dc.contributor.author | Bustillos, A. |
dc.contributor.author | Fear, S. |
dc.contributor.author | Ganta, S. |
dc.contributor.author | Blay, Jean-Yves |
dc.date.accessioned | 2022-08-10T06:26:17Z |
dc.date.available | 2022-08-10T06:26:17Z |
dc.date.issued | 2022-04 |
dc.identifier.citation | Tabernero J, Andre F, Blay JY, Bustillos A, Fear S, Ganta S, et al. Phase II multicohort study of atezolizumab monotherapy in multiple advanced solid cancers. ESMO Open. 2022 Apr;7(2):100419. |
dc.identifier.issn | 2059-7029 |
dc.identifier.uri | https://hdl.handle.net/11351/7976 |
dc.description | Inhibidor del punt de control PD-L1; Atezolizumab; Tumors sòlids |
dc.description.sponsorship | This study was supported by F. Hoffmann-La Roche (no grant number) who provided financial support for the conduct of study and were involved in study design; in the collection, analysis and interpretation of data; in the writing of the report; and in the decision to submit the article for publication. They also funded assistance with manuscript writing by a professional medical writer. |
dc.language.iso | eng |
dc.publisher | Elsevier |
dc.relation.ispartofseries | ESMO Open;7(2) |
dc.rights | Attribution-NonCommercial-NoDerivatives 4.0 International |
dc.rights.uri | http://creativecommons.org/licenses/by-nc-nd/4.0/ |
dc.source | Scientia |
dc.subject | Càncer - Tractament |
dc.subject | Anticossos monoclonals |
dc.subject.mesh | Neoplasms |
dc.subject.mesh | /drug therapy |
dc.subject.mesh | Antibodies, Monoclonal, Humanized |
dc.title | Phase II multicohort study of atezolizumab monotherapy in multiple advanced solid cancers |
dc.type | info:eu-repo/semantics/article |
dc.identifier.doi | 10.1016/j.esmoop.2022.100419 |
dc.subject.decs | neoplasias |
dc.subject.decs | /farmacoterapia |
dc.subject.decs | anticuerpos monoclonales humanizados |
dc.relation.publishversion | https://doi.org/10.1016/j.esmoop.2022.100419 |
dc.type.version | info:eu-repo/semantics/publishedVersion |
dc.audience | Professionals |
dc.contributor.organismes | Institut Català de la Salut |
dc.contributor.authoraffiliation | [Tabernero J] Servei d’Oncologia Mèdica, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. UVic-UCC, IOB-Quiron, Barcelona, Spain. [Andre F] Gustave Roussy Cancer Campus Grand Paris, Villejuif, France. [Blay JY] Centre Léon Bérard, Lyon, France. [Bustillos A, Fear S] Global Product Development, F. Hoffmann-La Roche Ltd, Basel, Switzerland. [Ganta S] Product Development Safety, F. Hoffmann-La Roche Ltd, Basel, Switzerland |
dc.identifier.pmid | 35305400 |
dc.identifier.wos | 000797892800010 |
dc.rights.accessrights | info:eu-repo/semantics/openAccess |